All Comments by Benjamin Wolozin

  1. Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease.
  2. Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia.
  3. Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway.
  4. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type.
  5. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.
  6. Designing drugs to stop the formation of prion aggregates and other amyloids.
  7. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease.
  8. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain.
  9. Essential role for cholesterol in synaptic plasticity and neuronal degeneration.
  10. Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation.
  11. Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling.
  12. Synucleins are a novel class of substrates for G protein-coupled receptor kinases.
  13. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.
  14. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin.
  15. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.